Physician profile
Elyse E Lake
NPI 1063721611
$4,249.93
in general payments reported to CMS, 2019-2025
25 companies · $878 in 2025
The $878 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $680 · 2022: $585 · 2023: $1,103 · 2024: $1,004 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,984.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $764.02 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.43 | 2021-2025 | Jardiance |
| Pfizer INC. | $357.03 | 2021-2025 | |
| Lilly USA, LLC | $252.49 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Abbott Laboratories | $157.46 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $108.19 | 2021-2025 | Rybelsus, Ozempic |
| Inspire Medical Systems, INC. | $93.11 | 2024-2025 | Inspire |
| Alkermes, INC. | $92.46 | 2024-2025 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.45 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $66.81 | 2023-2025 | Auvelity |
| Amgen INC. | $61.50 | 2023-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $57.38 | 2023-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $57.04 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $48.69 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $44.26 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $42.92 | 2023 | |
| Phathom Pharmaceuticals, INC. | $33.69 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $19.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.37 | 2021 | |
| Medtronic, INC. | $16.14 | 2025 | Inceptiv |
| Biohaven Pharmaceuticals, INC. | $15.85 | 2021 | |
| Cranial Technologies, INC | $14.31 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.73 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyse Lake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.